{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Napolitano A"],"funding":["V-Foundation","NCI DOD","NCI","Wellcome Trust and the Medical Research Council","Medical Research Council","NIMHD NIH HHS","NCI NIH HHS","University of Hawaii Foundation Honeywell International Inc.","Belluck and Fox, and the Stephen E. Banner Foundation","The Riviera United 4-a Cure, and Mesothelioma Applied Research Foundation and Shino-Test Corporation","Wellcome Trust","EDRN NCI"],"pagination":["3087-96"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4867109"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(12)"],"pubmed_abstract":["<h4>Purpose</h4>To determine whether serum levels of high mobility group box protein 1 (HMGB1) could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and unexposed controls.<h4>Experimental design</h4>Hyperacetylated and nonacetylated HMGB1 (together referred to as total HMGB1) were blindly measured in blood collected from malignant mesothelioma patients (n = 22), individuals with verified chronic asbestos exposure (n = 20), patients with benign pleural effusions (n = 13) or malignant pleural effusions not due to malignant mesothelioma (n = 25), and healthy controls (n = 20). Blood levels of previously proposed malignant mesothelioma biomarkers fibulin-3, mesothelin, and osteopontin were also measured in nonhealthy individuals.<h4>Results</h4>HMGB1 serum levels "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients."],"pmcid":["PMC4867109"],"funding_grant_id":["U01 CA111295","5U01CA111295–08","R01106567","R01 CA198138","G0700654","NCI-R01 CA160715, DOD CA120355","U54 MD007584","MR/L006758/1","R01 CA160715","P30 CA071789"],"pubmed_authors":["Yang H","Napolitano A","Pellegrini L","Pastorino S","Pass HI","Prokrym K","Canino C","Goparaju CM","Carbone M","Baumann F","Antoine DJ","Pagano I"],"additional_accession":[]},"is_claimable":false,"name":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.","description":"<h4>Purpose</h4>To determine whether serum levels of high mobility group box protein 1 (HMGB1) could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and unexposed controls.<h4>Experimental design</h4>Hyperacetylated and nonacetylated HMGB1 (together referred to as total HMGB1) were blindly measured in blood collected from malignant mesothelioma patients (n = 22), individuals with verified chronic asbestos exposure (n = 20), patients with benign pleural effusions (n = 13) or malignant pleural effusions not due to malignant mesothelioma (n = 25), and healthy controls (n = 20). Blood levels of previously proposed malignant mesothelioma biomarkers fibulin-3, mesothelin, and osteopontin were also measured in nonhealthy individuals.<h4>Results</h4>HMGB1 serum levels ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jun","modification":"2025-04-05T14:58:53.737Z","creation":"2019-03-27T02:13:39Z"},"accession":"S-EPMC4867109","cross_references":{"pubmed":["26733616"],"doi":["10.1158/1078-0432.CCR-15-1130","10.1158/1078-0432.ccr-15-1130"]}}